retatrutide dosing phase 2 trial VisualAbstract: reduces body weight by 17.5% in patients with obesity Retatrutide isn't a GLP-1. It's

That means you cannot legitimately place 10.8% for cagrilintide next to 24.2% for retatrutide and declare a winner, because those numbers come from different trials, different populations, different durations (26 vs 48 weeks), different doses, and critically a monotherapy figure for one versus a monotherapy figure for the other, while cagrilintides strongest data are actually as a combination

Our Reviews of Popular GLP-1 Alternatives Curious to learn more

This hormone helps regulate blood sugar and appetite, especially after eating

These drugs, like Wegovy (Semaglutide) and Zepbound (Tirzepatide), have been game changers

Retatrutide is not listed as a scheduled controlled substance under the international drug-control conventions or under the major national scheduling systems

Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial